Roads to remission: evolving treatment concepts in type 2 inflammatory diseases

Area of Science:

• Immunology
• Allergy and Clinical Immunology
• Pulmonology

Background:

• Non-communicable diseases (NCDs) characterized by type 2 inflammation, such as asthma and atopic dermatitis, are globally increasing.
• A paradigm shift in managing these conditions is emerging, focusing on disease modification and achieving remission.
• The concept of remission, initially applied to non-type 2 inflammatory diseases like rheumatoid arthritis, is now being adopted for type 2 inflammatory conditions.

Purpose of the Study:

• To review the evolution of remission as a treatment goal in type 2 inflammatory diseases.
• To discuss the underlying pathophysiology and therapeutic advancements driving this new paradigm.
• To identify challenges and future research directions for achieving remission in type 2 inflammatory NCDs.

Main Methods:

• Literature review of studies on type 2 inflammation and disease remission.
• Analysis of the pathophysiology of type 2 inflammatory diseases.
• Evaluation of current and emerging therapies targeting type 2 pathways.

Main Results:

• The concept of remission is novel but most advanced in asthma among type 2 inflammatory diseases.
• A better understanding of type 2 inflammation pathophysiology supports disease modification.
• Highly effective drugs selectively targeting type 2 pathways are enabling this new treatment approach.

Conclusions:

• Achieving remission represents a significant advancement in managing type 2 inflammatory NCDs.
• Further research is needed to address challenges and optimize remission strategies.
• The paradigm shift towards remission holds promise for improving patient outcomes in chronic inflammatory diseases.